If you asked for a show of hands...If you asked for a show of hands how many people want to be stuck with a needle in a matter of every few weeks vs. a matter of every few months? Does a single person put up their hand? Many are needlephobic and have a hard time with needles at all, period. There's the risk of needlestick injuries over a lifetime of use. There is also the inconvenience. Could administration of a drug that reduces administration to a matter of months also reduce the cost of the drug and its administration?Healthcare budgets are breaking and many are having difficulty affording food. There can also be a more consistent level of drug in the bloodstream with Q-Sphera creating potential superior health outcomes vs. a drug that needs to be injected more frequently. Q-Sphera could be a big game-changer in a startlingly large industry. The drugs Q-Sphera works with are already approved. It may be more of a formulation risk than a clinical trial risk as with xB3. Whereas xB3 is years behind competitors like Denali, Q-Sphera is a one and only. J&J is working on the technology for multiple drugs and Midatech's CEO believes the company could deliver a license in 2023. J&J is the world's largest healthcare company. He was hoping it would have been one of the catalysts to support a financing but it didn't make it. That sounds like it could be close. Big pharma marches to the beat of its own drummer as BTI knows; and J&J may have been trying to use Midatech's lack of cash as negotiating leverage. The monoclonal antibody market was US$154 billion in 2021. And no one wants unnecessary needles? What about the market size in 2027? How much market share could a game-changing technology like Q-Sphera be viewed as taking if J&J enters a licensing agreement in 2023 and what could the odds be of ultimate success? With Biodexa a therapeutics company with the infrastructure to advance its own pipeline what could it mean for valuation? Could a deal with J&J accelerate Q-Sphera licensing deals in 2023?
"No other company or acedemic institution has been able to do what we've done. We could have the world's first long acting injectable protein. Let me just say that it is not often that small companies like ours make these kinds of scientific leaps. This really is our Watson and Crick moment." Stephen Stamp CEO Midatech June 17, 2021
"The Company believes these results could potentially open up very significant opportunities for its Q-Sphera technology. A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors. In 2020, the top 10 mAbs recorded aggregate sales of US$74.9 billion1 and all mAbs US$154 billion1 globally." June 17, 2021
"Following expansion of the R&D collaboration agreement with Janssen for encapsulation of its experimental monoclonal antibody, the company is working on developing methods for encapsulation of bispecific T cell engager molecules and antibody-drug conjugates, both of which have shown utility in oncology and present considerable market opportunity." Edison Group November 15, 2022
"We continue to believe there is substantial value to be unlocked from Midatech's MTX110, particularly in our ongoing phase I clinical trial in GBM, and to leverage our Q-Sphera technology. In combination with Bioasis' promising development pipeline we have the opportunity to create a much stronger group and transition from a drug delivery platform-based company to a therapeutics company." Stephen Stamp CEO Midatech December 13, 2022